NCT06548919 2024-08-12Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast CancerSciClone PharmaceuticalsRecruiting450 enrolled
NCT06544577 2024-08-09Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBCSciClone PharmaceuticalsRecruiting350 enrolled